Chengdu Zenitar Biomedical Technology Co., Ltd
Clinical trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- A single-center, non-randomized, open-label, single-dose mass balance study of [¹⁴C]Purinostat mesylate for injection in healthy participants Results expected Oct 2026 (estimated)
- New hope for Hard-to-Treat lymphoma: experimental drug shows promise Results expected Dec 2026 (estimated)
- Can common drugs change how a new cancer medicine works? Results expected Dec 2026 (estimated)
- Can a new experimental pill be safely given to people? Results expected Jul 2027 (estimated)
- New pill could help control blood disorder when standard drugs fail Results expected Jul 2027 (estimated)
-
New pill could help control blood disorder when standard drugs fail
Disease control Recruiting nowThis study tests a new drug called flonoltinib maleate in 60 people with polycythemia vera (a condition where the body makes too many red blood cells) who cannot take or no longer respond to standard treatments. The goal is to see if the drug safely reduces red blood cell levels …
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New pill aims to shrink spleen in bone marrow cancer
Disease control Recruiting nowThis phase 3 trial tests a new drug called flonoltinib maleate in people with intermediate- or high-risk myelofibrosis, a type of bone marrow cancer. The study compares flonoltinib to an existing drug, ruxolitinib, to see if it can reduce spleen size and improve symptoms. About 1…
Phase 3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New hope for myelofibrosis patients who failed standard therapy
Disease control Recruiting nowThis study tests an experimental drug called flonoltinib maleate in about 64 people with a rare bone marrow cancer (myelofibrosis) that is moderate to high risk and has not responded to or stopped responding to standard JAK inhibitor therapy. Participants take a daily pill on an …
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
New pill could soothe severe eczema – trial underway
Disease control Recruiting nowThis study tests whether ZL-82 tablets can safely reduce eczema symptoms in adults with moderate to severe atopic dermatitis. About 111 participants will take either the drug or a placebo daily for 16 weeks, with regular checkups. The main goal is to see if ZL-82 improves skin se…
Phase 2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
New hope for Hard-to-Treat lymphoma: phase 3 trial launches
Disease control Recruiting nowThis phase 3 trial tests a new drug called purinostat mesylate against an existing drug, selinexor, in 390 adults with relapsed or refractory diffuse large B-cell lymphoma. Participants receive either purinostat mesylate by infusion or selinexor by mouth. The study aims to see wh…
Phase 3 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Jun 26, 2026 19:14 UTC
-
Can a new experimental pill be safely given to people?
Knowledge-focused Recruiting nowThis early-stage trial is testing an experimental tablet called ZL-65 in healthy adults aged 18 to 45. The main goal is to see if the drug is safe and tolerable when given as a single or multiple doses, and to learn how the body absorbs and processes it. The study also looks at w…
Phase 1 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC